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Abstract
Background: TP53 is one of major tumour suppressor genes being essential in preservation of
genome integrity. Two very common polymorphisms have been demonstrated to contribute to
cancer susceptibility and tumour behaviour. The purpose of this study was to evaluate the role of
Arg72Pro and PIN3 Ins16bp polymorphisms in TP53 gene as genetic susceptibility and predictive
markers to breast cancer.
Methods: We analysed DNA samples from 264 breast cancer patients and 440 controls, for TP53
Arg72Pro and PIN3 Ins16bp polymorphisms using PCR-RFLP.
Results: We observed that women with A2A2 genotype have increased risk for developing breast
cancer, either in women with or without familial history (FH) of the disease (OR = 4.40, 95% CI
1.60–12.0; p = 0.004; OR = 3.88, 95% CI 1.18–12.8; p = 0.026, respectively). In haplotype analysis,
statistically significant differences were found between TP53 Arg-A2 haplotype frequencies and
familial breast cancer cases and the respective control group (OR = 2.10, 95% CI 1.08–4.06; p =
0.028). Furthermore, both TP53 polymorphisms are associated with higher incidence of lymph
node metastases.
Conclusion: Our findings suggest TP53 PIN3 Ins16bp polymorphism as a real risk modifier in
breast cancer disease, either in sporadic and familial breast cancer. Furthermore, both TP53
polymorphisms are associated with higher incidence of lymph node metastases.
Background
Breast cancer have been associated with well-established
risk factors, such as high estrogen exposure, environmen-
tal factors (e. g. diet and ionizing radiation) and family
history [1,2]. Family history of breast cancer is a particu-
larly important high risk factor for this disease. Two genes
were identified as the major susceptibility genes in high
risk families, namely BRCA1 and BRCA2. However, these
genes account for only a minority of the overall family risk
of breast cancer [3]. Furthermore, approximately only
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10% of all breast cancer cases exhibit a familial pattern of
incidence [4,5]. In this way, the remaining familial and
sporadic risk may be due to common low to moderate
penetrance genetic variants, which are also referred as
genetic polymorphisms. One strong candidate for genetic
susceptibility factor to familial and/or sporadic breast can-
cer is the TP53 gene. This gene is frequently somatically
mutated in breast cancer [6,7] and TP53 germline muta-
tions are associated with increased risk for developing
diverse malignancies, including 25–30% of hereditary
breast cancer cases associated with Li-Fraumeni syndrome
[8]. Furthermore, based on its pivotal role in DNA damage
repair and its physical and functional interactions with
BRCA1 and BRCA2 proteins [9,10], TP53 seems to be a
strong candidate breast cancer predisposition.
The TP53 tumour suppressor gene, also designated the
guardian of the genome, is essential in preservation of
genome integrity. From the numerous biological func-
tions of p53 protein, inhibition of cell cycle progression,
DNA repair and apoptosis are the major cellular pathways
where it is involved [6].
TP53 gene mutations are widely detected in breast cancer,
being correlated with specific clinical phenotypes [11,12].
Predisposition to several human cancers has been associ-
ated with genetic polymorphisms, which may represent
an important contribution to cancer susceptibility and
tumour behaviour [13-16]. Several polymorphisms have
been identified within TP53 gene, both in non-coding and
coding regions [17]. One of the most well studied TP53
gene polymorphism is Arg72Pro, located in codon 72 on
exon 4, leading to arginine-proline substitution, which in
its turn results in a structural alteration of the protein [18].
Another common polymorphism is 16 base pair (bp)
duplication in intron 3 of the TP53 gene (PIN3 Ins16bp).
In this case-control study, we hypothesize that the two
common polymorphisms of TP53 gene play a role either
apoptosis, cell cycle control efficiency, as well as DNA
repair capacity, which ultimately may contribute to an
increase of breast cancer susceptibility within familial
and/or sporadic cases, as well as represent an additional
tool for prognosis prediction.
Methods
Study Population
We analysed a total of 264 DNA breast cancer cases: 73
unrelated familial breast cancer cases were selected from
the Oncology and Surgical Departments from S. João Hos-
pital at Porto and Vigo Hospital, and 191 unrelated spo-
radic breast cancer cases were recruited from IPO-Porto
(Oncology Portuguese Institute), during 1998–2003,
from patients that were receiving treatment. All cases were
histological confirmed at the Department of Pathology.
Clinico-pathological parameters were obtained when pos-
sible from hospital clinical records. Familial case group
presented a mean age of 42.07 years, with an age range of
24–77 years. The high-risk familial breast cancer group,
also designated by us as family history (FH) breast cancer
cases, included women with the follow features, based on
the Breast Cancer Linkage Consortium criteria [19]: early
onset (≤40 years) and/or bilaterality; or more than three
cases of breast cancer in the family; or more than one case
of ovarian cancer in the family; or more than two first-
degree relatives involved; or male breast cancer. These
high-risk breast cancer cases are BRCA1/BRCA2 mutations
non-carriers [20]. Sporadic cases group (with no presence
of FH) presented a mean age of 53.41 years, with an age
range of 41–88 years. Control women were randomly
selected from blood banks in the same region during the
same time period as the cases were collected. The selection
criteria include no prior history of cancer, and controls
were frequency matched to the cases by age (± 5 years). A
total of 440 healthy women presenting a median age of
42.29 years and an age range of 21–85 years, were used as
control group of familial breast cancer cases. From the
above control group 216 healthy women were selected
according to the age of diagnosis of the sporadic breast
cancer patients group (higher than 40 years), with a
median age of 53.05 and an age range of 41–85, being
used as control group of sporadic breast cancer cases. All
participants provided informed consent. Ethical approval
was obtained by the specific institutions ethical commit-
tees.
Laboratory Methods
Genomic DNA was isolated from lymphocytes of
peripherical blood using Puregene® DNA Purification Kit
(Gentra Systems, Minneapolis, USA). All the polymor-
phisms were assessed by PCR-RFLP technique. TP53
Arg72Pro  polymorphism (rs1042522) was detected by
amplifying genomic DNA with the forward primer 5'-GAA
GAC CCA GGT CCA GAT GA-3' and the reverse primer 5'-
CTG CCC TGG TAG GTT TTC TG-3'. The PCR amplifica-
tion parameters were 32 cycles each of 30 sec at 94°C, 30
sec at 54°C, and 30 sec at 72°C. The 152 bp PCR product
was digested with Bsh1236I (Fermentas, Ontario, Canada)
at 37°C overnight. Digested products were separated by
electrophoresis in a 3% agarose gel (Seakem® LE Agarose,
Rockland, USA) and visualized by ethidium bromide
staining. Wild type alleles resulted in 50 and 102 bp frag-
ments and the variant alleles resulted in 152 bp fragment
following restriction enzyme digestion. TP53 PIN3
Ins16bp  polymorphism (rs17878362) was detected by
amplifying genomic DNA with the forward primer 5'-CTG
AAA ACA ACG TTC TGG TA-3' and the reverse primer 5'-
AAG GGG GAC TGT AGA TGG GTG-3'. The PCR amplifi-
cation parameters were 32 cycles each of 30 sec at 94°C,BMC Cancer 2008, 8:32 http://www.biomedcentral.com/1471-2407/8/32
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30 sec at 60°C, and 30 sec at 72°C. The PCR product was
separated by electrophoresis in a 4% agarose gel (Seakem®
LE Agarose, Rockland, USA) and visualized by ethidium
bromide staining. Wild type alleles, designated A1 allele
(no duplication) resulted in 119 bp fragment and the var-
iant alleles, designated A2 allele (with 16 bp duplication)
resulted in 135 bp fragment.
To ensure quality control of all genotyping results, 10% of
the samples was randomly selected and sequenced using
an ABI automated sequencer. We obtained a 98% of con-
cordance between the genotyping results acquire by the
two methods.
Statistical Analysis
Analysis of data was performed using the computer soft-
ware SPSS version 14.0 (SPSS Inc., Chicago, USA). Chi-
square (χ2 test) analysis was used to compare categorical
variables. Whenever necessary, the Fisher test was used
when number of samples was equal or inferior to 5. A 5%
level of significance was used in the analysis. The Odds
Ratio (OR) and its 95% confidence interval (CI) were cal-
culated to measure the association between TP53 poly-
morphic genotypes and breast cancer risk. Logistic
regression analysis was used to calculate the adjusted OR
and 95% CI for the influence of TP53 genotypes in the risk
of breast cancer, adjusted for age and/or FH. Whenever
appropriate, the observed number of each genotype in
control groups were compared with that expected for a
population in the Hardy-Weinberg Equilibrium by using
a goodness of fit χ2 test. The frequencies of expected hap-
lotypes were estimated by using the statistical methodolo-
gies implemented by HPlus software [21], which infers
haplotypes based on expectation-maximization with a
modified progressive ligation computational algorithm.
The nonparametric test, Kruskal-Wallis test, was used to
compare mean age of diagnosis between the different gen-
otype polymorphisms.
Results
The distribution of the genotype frequencies in PIN3
Ins16bp polymorphisms among control group (p = 0.478)
and in Arg72Pro and PIN3 Ins16bp among control sub-
group (p = 0.082 and p = 0.294) is in agreement with
those expected under Hardy-Weinberg equilibrium,
excepted for Arg72Pro in the overall control group (p =
0.013).
Concerning TP53 Arg72Pro polymorphism in the familial
breast cancer cases, frequencies of Arg72Arg, Arg72Pro and
Pro72Pro were 53.4%, 34.2% and 12.3%, respectively. In
sporadic breast cancer, 56.0%, 34.9% and 9.1% were
homozygous for 72Arg  allele, heterozygous and
homozygous for 72Pro allele, respectively. No statistically
significant associations were found between the TP53
Arg72Pro polymorphism and risk of familial and sporadic
breast cancer risk (Table 1).
Frequencies of TP53 PIN3 Ins16bp polymorphism geno-
types were 65.7% to A1A1, 21.4% to A1A2 and 12.9% to
A2A2, in familial breast cancer cases. Regarding sporadic
breast cancer group, we observed 63.9%, 29.3% and 6.8%
frequencies for homozygous for A1 allele, heterozygous
and homozygous for A2 allele, respectively. We observed
that A2A2 genotype carriers with positive FH were at a
4.40-fold (95% CI = 1.60–12.0; p = 0.004) increased risk
of breast cancer compared with the respective control
group. Moreover, statistically significant differences were
Table 1: TP53 Arg72Pro and PIN3 Ins16bp genotypic and allelic frequencies. Association with familial and sporadic breast cancer risk.
TP53 Polymorphism Genotype Positive FH Cases Controls OR* (95% CI) Sporadic Cases Controls OR* (95% CI)
Arg72Pro
Arg/Arg 39 (53.4) 256 (59.0) Reference 98 (56.0) 124 (58.5) Reference
Arg/Pro 25 (34.2) 142 (32.7) 1.19 (0.68–2.08) 61 (34.9) 70 (33.0) 1.26 (0.79–2.02)
Pro/Pro 9 (12.3) 36 (8.3) 1.58 (0.68–3.67) 16 (9.1) 18 (8.5) 1.35 (0.63–2.88)
Alleles
Arg 103 (70.5) 654 (75.3) Reference 257 (73.4) 318 (75.0) Reference
Pro 43 (29.5) 214 (24.7) 1.28 (0.85–1.91) 93 (26.6) 106 (25.0) 1.09 (0.78–1.52)
PIN3 Ins16bp
A1A1 46 (65.7) 299 (68.0) Reference 122 (63.9) 147 (68.1) Reference
A1A2 15 (21.4) 130 (29.5) 0.80 (0.43–1.49) 56 (29.3) 65 (30.1) 1.07 (0.67–1.70)
A2A2 9 (12.9) 11 (2.5) 4.40 (1.60–12.0) 13 (6.8) 4 (1.9) 3.88 (1.18–12.8)
Alleles
A1 107 (76.4) 728 (82.7) Reference 300 (78.5) 359 (83.1) Reference
A2 33 (23.6) 152 (17.3) 1.48 (0.94–2.31) 82 (21.5) 73 (16.9) 1.34 (0.93–1.94)
* OR adjusted for age (logistic regression analysis)
FH – family history; OR – odds ratio; CI – confidence intervalBMC Cancer 2008, 8:32 http://www.biomedcentral.com/1471-2407/8/32
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observed in A2A2 genotype frequencies comparing spo-
radic breast cancer cases and respective control group (p =
0.026). Our results showed that carriers of A2A2 genotype
with no FH present an increased risk of breast cancer (OR
= 3.88, 95% CI 1.18–12.8).
We investigated haplotype effects of the two polymor-
phisms studied in breast cancer risk (Table 2). Compared
the common TP53 Arg-A1 haplotype with the other
expected haplotypes; we only observed statistically signif-
icant differences regarding TP53 Arg-A2 haplotype
between the familial breast cancer cases and respective
control group (p = 0.028). Carriers of TP53 Arg-A2 haplo-
type and presence of FH of breast cancer presented an
increased risk of develop breast cancer (OR= 2.10; 95% CI
1.08–4.06).
We examined the relationship between age at onset and
genotypes and found a positive correlation in the FH
group. The mean age of FH patients group with A2A2 gen-
otype was 33.43 (± 8.08) years, whereas the mean age of
patients with A1A1  and A1A2  genotypes was 42.44 (±
12.14) and 44.80 (± 10.85) years, respectively (Kruskal
Wallis test p = 0.056). Therefore, the carrier's status of
A2A2 genotype was associated with an earlier age at onset
cancer with respect to the patients with A1  genotypes.
However, this difference was in the frontier of statistically
significant, possibly because of the smaller size of the
group (7 patients to Pro/Pro genotype). No association
was observed relating age at onset and Arg72Pro polymor-
phism (Kruskal Wallis test p = 0.747).
The analysis of the TP53 polymorphisms with respect to
some clinical pathological showed a significant associa-
tion of Pro or A2 genotypes with the presence of lymph
node metastases (p = 0.009 and p < 0.001, respectively,
adjusted for age and breast cancer family history, using
logistic regression analysis).
Discussion
Breast cancer is an heterogeneous disease, as sustained by
wide variable morphological appearance, many risks fac-
tors and distinct gene expression profile [2,22]. Common
genetic alterations (e.g. polymorphisms), with possible
effects on function and/or protein expression, within
genes involved in essential cellular pathways, such as car-
cinogen metabolism, DNA repair, cell cycle control and
cell proliferation, could predispose individuals to cancer
[15,23-25], including breast cancer [15,26-29].
The TP53 is one of the major tumour suppressor genes
which carry out essential functions in preservation of
genome integrity. Thus, when the cell is under stress, par-
ticularly stress which will involve DNA damage, p53 pro-
motes growth arrest, allowing the cell to repair the DNA
lesions. If the damage is excessively hazardous, then p53
will lead to cell apoptosis. Several genetic polymorphisms
have been described in TP53 gene [18] and some of these
variants seem to confer different functions among the p53
[30-32].
In the present study, we evaluated two separate TP53 pol-
ymorphisms, Arg72Pro and PIN3 Ins16bp, in two groups
of breast cancer, familial and sporadic cases, as well as in
matching control groups. The allelic frequencies of our
control group for the different polymorphisms are in
accordance with earlier reports from European popula-
tions [16,33]. We found a deviation from Hardy-Wein-
berg equilibrium in overall group of controls for Arg72Pro
P53 polymorphism genotypes. Hardy-Weinberg equilib-
rium depends on a series of features about the tested pop-
ulation, including, for example the sample population
size, random mating, no migration, no genetic drift and
no selection taking place [34]. Thus, this deviation could
be due to chance or violation of these assumptions, being
the possibility of genotyping errors lower, since 10% our
control sample genotyping were confirmed by direct
sequence and its were similar with other European popu-
lations.
Concerning the codon 72 TP53 polymorphism (Arg72Pro),
we did not find any association between this polymor-
phism and breast cancer. Our results are in agreement
with other studies [33,35,36], however, the literature
remains highly controversial regarding the role of this pol-
ymorphism in breast cancer risk [37-42]. One study
showed that TP53 72Pro variant induces transcription acti-
vation more efficiently than TP53 72Arg variant [40]. On
the other hand, other authors revealed that TP53 72Pro
variant induce cell cycle arrest better than 72Arg  [31].
Table 2: Expected haplotype frequencies between Arg72Pro and PIN3 Ins16bp polymorphisms. Association with familial and sporadic 
breast cancer risk.
Haplotypes Positive FH Cases Controls OR (95% CI) Negative FH Cases Controls OR (95% CI)
Arg-A1 0.607 0.711 Reference 0.695 0.705 Reference
Arg-A2 0.091 0.041 2.10 (1.08–4.06) 0.048 0.045 1.06 (0.53–2.12)
Pro-A1 0.150 0.111 1.49 (0.86–2.58) 0.098 0.119 0.80 (0.49–1.32)
Pro-A2 0.151 0.137 1.27 (0.72–2.24) 0.160 0.131 1.27 (0.83–1.95)
FH – family history; OR – odds ratio; CI – confidence intervalBMC Cancer 2008, 8:32 http://www.biomedcentral.com/1471-2407/8/32
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Other studies have showed that TP53 72Arg variant is
more efficient in inducing apoptosis [32,42]. Beside apop-
tosis and cell cycle control, p53 protein seems to be crucial
in the regulation of the different DNA repair pathways
[43]. A recent study demonstrated the influence of TP53
Arg72Pro in DNA repair capacity, showing that TP53 72Pro
variant activates several TP53  dependent target genes
involved in DNA repair and DNA damage repair much
more efficiently than the 72Arg variant expressing cells
[30]. These contradictory results could be explained by the
differential effects of this alteration in p53 function. Sev-
eral in vitro evidences have demonstrated that both TP53
Arg72Pro variants may selectively regulate specific cellular
functions.
In  TP53 PIN3 polymorphism, our findings suggest an
association of A2A2 genotype and increased breast cancer
risk among women with FH and sporadic breast cancer,
suggesting that this polymorphism contributed to
enhance susceptibility for breast cancer among Portu-
guese population, regardless of the presence of FH. Our
results are supported by previously reported studies sug-
gesting an association of PIN3 A2 genotypes with breast
cancer risk [44]. Although, the biological effect of the
TP53 PIN3 Ins16bp polymorphism is currently unclear,
theoretically, this polymorphism could affect mRNA
splicing, altering the coding regions and therefore being
implicated in regulation of gene expression and DNA-pro-
tein interactions, resulting in a defective protein [45,46].
Until now, just a single study had show PIN3 A2 allele
presents reduced mRNA stability [47].
The linkage disequilibrium between TP53  polymor-
phisms region could be an important factor affecting the
incidence of cancer in general [48,49], and breast cancer,
in particular [42,44,50]. Thus, haplotype analysis would
be important to confirm the significance of this variant on
breast cancer susceptibility. A statistical significant associ-
ation was found between Arg-A2  haplotype and breast
cancer susceptibility among women with FH of breast
cancer. On the other hand, a recent study has found that
Pro-A1  haplotype individuals present increased breast
cancer risk, however, in BRCA2 mutation carriers [42].
Nevertheless, other reports have also demonstrated a pos-
itive association of Arg-A2 haplotype with cancer [44,48].
Moreover, functional studies have shown that, in a spe-
cific haplotype combination, A2 allele is associated with
decreased apoptotic and DNA repair capacity [33,48].
Our findings suggest the Pro/Pro and A2A2 TP53 geno-
types as predictor factors for the presence of lymph node
metastases, being in agreement with previously functional
studies in the biological consequences of these variations
in P53 protein functions [40,47].
The natural history of breast cancer can be influenced by
several factors. We hypothesize that under the influence of
TP53 genetic polymorphisms, chronic exposure to higher
levels of several endogenous (e.g. estrogens) and exoge-
nous breast carcinogens resulting in consequent higher
accumulation of DNA damage during an individual's life-
time, may alter the age at onset of disease. Moreover, it has
been suggested that TP53 polymorphisms are associated
to familial breast cancer by the age of 50 years [33]. Our
results are consistent with this hypothesis, since TP53
PIN3 Ins16bp polymorphism seems to influence directly
the age to onset of familial breast cancer.
Conclusion
In conclusion, our findings suggest TP53 PIN3 Ins16bp
polymorphism as a real risk modifier in breast cancer dis-
ease, either in sporadic and familial breast cancer. Subse-
quently, these results will be crucial in the
characterization of the genetic breast cancer susceptibility
profile, within familial breast cancer cases non-carriers of
BRCA1/BRCA2 mutations. Furthermore, our findings sug-
gest TP53 Arg72Pro and PIN3 Ins16bp polymorphisms as
predictive factors of presence of lymph node metastases.
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